Jia-Xiong Kang, Chao Li, Yi-Mei Cheng, Mou-Xin Huang, Guang-Kuan Zhao, Zhi-Liang Jin, Xiao-Wei Qi, Jing Gu and Qin Ouyang* Pages 1 - 46 ( 46 )
As members of the protein tyrosine kinase family, the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) play essential roles in cellular signal transduction pathways. Overexpression or abnormal activation of EGFR and HER2 can lead to the development of various solid tumors. Therefore, they have been confirmed as biological targets for the development of anticancer drugs. Due to the fact that many cancers are highly susceptible to developing resistance to single-target EGFR inhibitors in clinical practice, dual inhibitors that target both EGFR and HER2 have been developed to increase efficacy, reduce drug resistance and interactions, and improve patient compliance. Currently, a variety of EGFR/HER2 dual inhibitors have been developed, with several drugs already approved for marketing or in clinical trials. In this review, we summarize recent advancements in small-molecule EGFR/HER2 dual inhibitors by focusing on structure-activity relationships and share novel insights into developing anticancer agents.
Epidermal growth factor receptor,Human epidermal growth factor receptor 2,Dual inhibitors,Anti-cancer agents,(NSCLC),Cancer